Welcome to our dedicated page for Xeris Biopharma Holdings SEC filings (Ticker: XERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Xeris Biopharma Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Xeris Biopharma Holdings's regulatory disclosures and financial reporting.
On July 15, 2026, Xeris Biopharma Holdings, Inc. completed privately negotiated exchange transactions with certain holders of its 8.00% Convertible Senior Notes due 2028. These holders exchanged approximately $23 million in aggregate principal amount of the notes for approximately 5.0 million shares of common stock and approximately $23 million in cash, funded with liquidity on-hand, and the exchanged notes were immediately cancelled.
Separately, a holder of $10.5 million in principal amount of the 2028 notes elected to convert those notes into approximately 3.6 million shares of common stock. After the exchange transactions and this conversion, no 2028 notes remain outstanding. Shares issued in the exchanges relied on the Section 4(a)(2) exemption under the Securities Act, while shares issued in the conversion relied on Section 3(a)(9), with exchanging noteholders representing accredited investor and qualified institutional buyer status.
Xeris Biopharma Holdings insider Steven Pieper reported open-market sales of 45,000 shares of common stock over two days. He sold 27,600 shares on July 7, 2026 at a weighted average price of $8.5245 per share and 17,400 shares on July 6, 2026 at $8.50 per share.
After these transactions, Pieper directly holds 1,366,053 Xeris Biopharma shares. The filing notes the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025, and that his holdings include 2,113 shares acquired on June 30, 2026 through the company’s Employee Stock Purchase Plan.
Morgan Stanley Smith Barney LLC reported a Form 144 disclosure showing Steven Pieper sold 17,400 shares of Common Stock on 07/06/2026 for $147,900. The filing also lists prior issuer transactions including a 4,600-share open-market purchase on 05/17/2017 and 23,000 Restricted Stock Units dated 12/28/2017.
XERS reported insider transactions including an open-market purchase of 400 common shares and an issuance of 17,000 restricted stock units (RSUs). The filing lists transaction dates of 05/17/2017 for the purchase and 12/28/2017 for the RSU award; the cover shows 07/06/2026 as a filing header date. The actions are recorded as an open-market purchase and an issuer grant.
Xeris Biopharma Holdings director Nerissa Kreher received equity-based compensation. She was granted 33,582 shares of common stock through restricted stock units under the company’s 2018 Stock Option and Incentive Plan. These RSUs vest in equal annual installments over three years, contingent on continued board service.
She was also granted stock options for 37,910 shares of common stock at an exercise price of $8.00 per share, expiring on July 1, 2036. These options vest in equal annual installments over three years, also subject to continued service on the board. The filing shows no open-market buying or selling, only compensation-related awards.
Xeris Biopharma Holdings, Inc. filed a Form 3 naming Nerissa Kreher as a reporting person in the capacity of a director. The filing’s transaction summary shows no reported buying, selling, acquiring, disposing, or other share transactions, with all transaction counts and share amounts listed as zero.
Xeris Biopharma Holdings officer Kevin McCulloch reported an open-market sale of 90,000 shares of common stock at a weighted average price of $8.0279 per share on July 1, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025.
After the transaction, McCulloch directly owns 1,691,126 shares of Xeris Biopharma common stock. An additional 25,000 shares are held indirectly by his spouse, including 3,401 shares acquired on June 30, 2026 under the company’s 2018 Employee Stock Purchase Plan, with beneficial ownership of those indirect shares disclaimed except for any pecuniary interest.
Xeris Biopharma Holdings, Inc. officer Beth Hecht reported an open-market sale of 16,666 shares of common stock at a weighted average price of $8.0319 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025.
After this sale, Hecht directly holds 1,161,128 Xeris Biopharma shares, indicating she retains a substantial equity position. Her holdings include 1,288 shares acquired on June 30, 2026 under the company’s 2018 Employee Stock Purchase Plan, showing ongoing participation in employee ownership programs.
Company filings show proposed insider sales under Rule 144. The excerpt lists scheduled 10b5-1 sales by Beth Hecht of 16,667 shares on 05/01/2026 and 06/01/2026, with gross proceeds reported as $103,805.37 and $100,982.35 respectively. The filing also lists prior acquisitions including 37,409 RSUs (01/31/2023), 10,026 ESPP shares (06/30/2020), and 2,563 open-market purchases (03/13/2020).